NCT01201018已完成1 期
A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment - A Phase I Study
Oshadi Drug Administration1 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2011年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 7
- 试验地点
- 1
- 主要终点
- Adverse events, serious adverse events occurrence
研究概览
简要总结
The study will be non randomized, open label, dose rising study in cancer patients. Cancer treatment is consisting of 2 different drugs: Oshadi D and Oshadi R that will be administered orally.
The study will include two sessions:
- A single dose period to evaluate acute toxicity of each drug
- Consecutive multiple increment dose escalation period of both drugs to determine the long-term safety, and the anticancer activity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically/ cytological proven solid tumor that is metastatic.
- •Age > 21 years old.
- •ECOG Performance status <
- •Documented progressive metastatic disease according to RECIST criteria.
- •At least one lesion not within prior radiation field that is measurable per RECIST.
- •Primary tumor must have been resected.
- •Four weeks must elapse from prior therapy.
- •Patient has recovered to CTCAE < Grade 1 from toxicities related to previous treatment (except non-clinically significant AEs).
- •Patient must have adequate organ function.
- •Sexually active fertile patients and their partners must agree to use medically accepted methods of contraception during therapy and 3 months after the last dose of the study drugs.
- •Female patients of childbearing potential must have a negative pregnancy test at screening.
- •Patient must understand and be willing to give written informed consent prior to any study procedures or evaluations and be willing to adhere to all study schedules and requirements.
- •Life expectancy > 6 months.
排除标准
- •Uncontrolled Intercurrent illness or any history of significant cardiac, renal, neurologic, metabolic, pulmonary, gastrointestinal, hematologic abnormality, chronic hepatic disease or any other disease which in the judgment of the investigator would interfere with the study or confound the results.
- •Current or history of hematologic malignancies.
- •Patient with positive HIV serology at screening.
- •Female patient who are breastfeeding or have a positive pregnancy test at screening or at any time during the study.
- •Radiation therapy < 4 weeks prior to screening.
- •Patient has received any other type of investigational agent < 4 weeks prior to screening.
- •Metastatic brain or meningeal disease.
- •Patient has prothrombin time/International Normalization Ration (PT/INR) or partial thromboplastin time (PTT) test results > 1.3 UNL.
- •Significant swallowing disorders.
- •Small bowel surgery.
- •Pelvic or abdominal radiation.
- •Pre-existing mal absorption syndrome, irritable bowel syndrome or other clinical situation which could affect oral absorption.
- •Evidence of concurrent (< 5 years) second malignancy other than basal cell carcinoma of the skin or cervical carcinoma in situ.
- •Mental disorders.
- •Inability to give written informed consent.
研究组 & 干预措施
Oshadi DR
Experimental
干预措施: Oshadi D, Oshadi R (Drug)
结局指标
主要结局
Adverse events, serious adverse events occurrence
时间窗: 6 months
次要结局
- Modified "Response Evaluation Criteria in Solid Tumors" (RECIST, Appendix 3) will be used.(6 months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell MalignanciesB-Cell LymphomaB-Cell LeukemiaB-cell TumorsNCT05932173920th Hospital of Joint Logistics Support Force of People's Liberation Army of China60
已完成
1 期
A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced MelanomaAdvanced MelanomaNCT02738489Jiangsu HengRui Medicine Co., Ltd.36
招募中
1 期
JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid TumorsHER2-Positive Solid TumorsNCT04280341Peking University50
已完成
1 期
Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid TumorsMalignant Solid TumourNCT01184807Otsuka Beijing Research Institute51
已完成
1 期
A Study to Determine the Safety and Attack Rate of the Seasonal Flu in Healthy VolunteersInfluenza, HumanNCT04372719SGS Life Sciences, a division of SGS Belgium NV36